undefined undefined
NaN.000
NaN.00%
Biontech Se Sponsored Adr (BNTX) has released an update. At BioNTech’s Annual G...
05-18 05:28
The European Patent Office has reportedly upheld the validity of Moderna’s (NASDAQ:MRNA) 949 patent for its COVID-19 vaccine in an ongoing dispute between the company and rival vaccine makers Pfizer (...
05-18 01:25
Amidst today's fast-paced and highly competitive business environment, it is cr...
05-17 23:00
让市场想不到的是,才在今年4月透露重组疫苗业务并裁员的赛诺菲(SNY.US)选择在现在这个时间点花12.7亿美元高调从Novavax引进新冠疫苗Nuvaxovid。
05-15 17:18
格隆汇5月15日|Evercore ISI Group:首次覆盖BioNTech,予其“与大市同步”评级,目标价为100美元。
05-15 17:10
Evercore ISI launched its coverage with a bullish view on a number of biotech stocks on Tuesday, citing a more constructive view on the sector, which is seeing signs of recovery after years of underpe...
05-14 23:24
来源:华兴资本 “华兴资本医疗与生命科技行业周报”定期发布,专注从资本角度解读一周数据,并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域,目...
05-13 09:30
文|氨基观察 在生物科技的竞技场中,没有梦想的玩家就像是失去了灵魂的咸鱼,徒有其表而缺乏内在的活力。 伴随着资本市场的潮起潮落,许多生物技术公司的真实写照或许...
05-11 15:59
一份合作协议引爆股价。周五美股盘前,诺瓦瓦克斯医药(NVAX.US)宣布,与法国制药巨头赛诺菲(SNY.US)达成了一项价值数十亿美元的合作协议。根据协议,双方将从明年开始联合商业化诺瓦瓦克斯医药的新冠疫苗,并共同开发针对冠状病毒和流感的组合疫苗。受消息刺激,诺瓦瓦克斯医药美股大幅上涨,一度涨近150%。截至发稿,公司股价仍涨超130%,报10.419美元/股,总市值14.63亿美元。获巨头注资12亿美元公开资料显示,诺瓦瓦克斯医药公司是一家新型临床阶段生物制药公司,致力于发现、开发和商业化纳米颗粒重组疫苗和佐剂。在周五公布的合作协议中,赛诺菲将利用诺瓦瓦克斯医药的新冠疫苗和旗舰疫苗技术Mat...
05-10 23:53
Novavax (NASDAQ:NVAX) shares hit a 52-week high on Friday as the COVID-19 vaccine maker removed its going-concern notice with its Q1 2024 financials on the back of a licensing deal with Sanofi (SNY), ...
05-10 23:15